SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 202 filers reported holding SAGE THERAPEUTICS INC in Q1 2024. The put-call ratio across all filers is 1.12 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $62,305 | -73.7% | 3,325 | -69.6% | 0.00% | -78.6% |
| Q4 2023 | $236,931 | -26.2% | 10,934 | +10.1% | 0.01% | +16.7% |
| Q2 2022 | $321,000 | +10.7% | 9,927 | +13.4% | 0.01% | +20.0% |
| Q1 2022 | $290,000 | +61.1% | 8,751 | +106.9% | 0.01% | +66.7% |
| Q4 2021 | $180,000 | -13.0% | 4,230 | -9.6% | 0.01% | -14.3% |
| Q3 2021 | $207,000 | +1625.0% | 4,678 | +1035.4% | 0.01% | +40.0% |
| Q1 2020 | $12,000 | -88.1% | 412 | -70.6% | 0.01% | -79.2% |
| Q4 2019 | $101,000 | -31.3% | 1,400 | +33.3% | 0.02% | -42.9% |
| Q3 2019 | $147,000 | +234.1% | 1,050 | +333.9% | 0.04% | +250.0% |
| Q2 2019 | $44,000 | -48.2% | 242 | -59.9% | 0.01% | -58.6% |
| Q3 2018 | $85,000 | +193.1% | 603 | +222.5% | 0.03% | +190.0% |
| Q2 2018 | $29,000 | +625.0% | 187 | +179.1% | 0.01% | +233.3% |
| Q3 2017 | $4,000 | -90.9% | 67 | -89.1% | 0.00% | -94.8% |
| Q1 2017 | $44,000 | – | 613 | +8657.1% | 0.06% | – |
| Q4 2016 | $0 | – | 7 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |